Order Entry
United States
ContactUsLinkComponent
Mouse- / Rat-IGFBP-2 ELISA , Eagle Biosciences
Mouse- / Rat-IGFBP-2 ELISA , Eagle Biosciences
Catalog # 102994-282
Supplier:  Eagle Biosciences
CAS Number:  
Mouse- / Rat-IGFBP-2 ELISA , Eagle Biosciences
Catalog # 102994-282
Supplier:  Eagle Biosciences
Supplier Number:  E08
CAS Number:  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

Specifications

  • Primary antibody reactivity:
    Mouse
  • Target protein:
    IGFBP-2
  • Description:
    Mouse- / Rat-IGFBP-2 ELISA
  • Size:
    1 kit
  • Cat. No.:
    102994-282
  • Supplier no.:
    E08

Specifications

About this item

Mouse/Rat IGFBP-2 ELISA is suited for the measuring of IGFBP-2 in the mouse and the rat serum.

  • Dynamic Range: 0.01 - 200 ng/mL
  • Sensitivity: 0.01 ng/mL
  • Incubation: 3 hours

Insulin-like growth factors (IGFs) regulate the proliferation, differentation, apoptosis, cell adhesion and metabolism in various tissues and cell types IGFBP-2 is an unglycosylated polypetide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation. The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission (5-10). During the GH-therapy, e.g. in short stature and in GH-abuse (doping) the IGFBP-2 level decreases. In Trisomy 18 IGFBP-2 in maternal serum is decreased and IGFBP-1 is increased; therefore the ratio IGFBP-2 /IGFBP-1 is a marker for this chromosome abnormality (17). Transgenic organisms are a good opportunity to investigate the function of genes or proteins. The mouse or rat model is a well-suited system for investigation of the relevance of IGFBP-2 in physiological and pathological processes. Over expression of the IGFBP-2 gene in mice results in a weight reduction of 30% in spleen and moderately reduced weight in other organs (18). Effects of IGFBP-2 on the organism can be compensated through the modified expression of other IGF Binding proteins. Especially in tumor biology the mouse and rat systems enable investigation of the systemic relevance of IGFBP-2. IGFBP-2 influences tumor cells as it induces catalase activity in adrenocortical cells (19). Furthermore IGFBP-2 interacts with tumor cells via its RGD-amino acid sequence and seems to stimulate cell invasion of glioma cells (20).